Services
Carasec’s experience in funding and advising companies through the commercialisation pathway and onto the ASX means we are ideally placed to provide advice to companies from incorporation all the way through to ASX listing and post listing market support, while providing curated investment opportunities to sophisticated and wholesale investors.
Investment Clients
-
Private seed and pre-IPO placements
-
Initial public offers
-
ASX placements
-
Rights issue shortfall offers
-
Execution and trading
Corporate Clients
-
Capital raising
-
Prospectus and ASX capital raising advice and documentation preparation
-
Underwriting services
-
Project and technology acquisition and divestment
-
Merger and acquisition advice
Our team has long standing relationships with third party service providers in the company secretary, accounting, intellectual property and management consulting sectors. As our client’s needs arise we introduce our trusted third party service providers who seamlessly integrate within the Carasec service offering.
Transactions previously managed by Carasec advisors
EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. EMVision was incoporated in 2017 to commercialise technology that originated at the University of Queensland.
​
Carasec Executive Director, Ryan Laws, is a co-founder of EMVision Medical Devices.
​
As a co-founder of EMVision, Ryan raised capital for the company via a seed raising at 8c per share in late 2017, a pre-IPO raise at 16c in mid 2018 and a 25c IPO in late 2018. EMVision traded as high as $4.20 in 2020.
​
Group 6 Metals Limited (ASX:G6M), formerly named King Island Scheelite Limited (ASX:KIS), is an Australian resources exploration and development company with a focus on the redevelopment of its 100%-owned Dolphin Tungsten Mine located on King Island, Tasmania.
The Dolphin Tungsten Mine hosts the highest-grade tungsten deposit of significant size in the Western world. Carasec advisors identified the opportunity in 2018 and provided corporate advice, focusing on project financing and investor egnagement. Members of the Carasec team led a number of consecutive capital raises, with one being corner-stoned by the Swiss investment company D.A.CH.S Capital AG.
4DS Memory Limited (ASX:4DS) is developing emerging non-volatile memory called "ReRAM" (or RRAM) with demonstrated technological advantages over other known ReRAM cells in development. This makes it a potential candidate to replace the current standard, DRAM, as the dominant standard of the future.
Advisors at Carasec identified the opportunity in 2017 and issued a research note to clients, which was followed by a capital raise at $0.04.
4DS Memory traded as high as $0.28 in January 2021.
Argenica Therapeutics Limited was incorporated in November 2019 to undertake development and commercialisation of a novel therapeutic developed by researchers at the University of Western Australia to protect the brain following stroke and other traumatic brain injuries.
Advisors at Carasec were involved in early seed capital raises, the preparation of the prospectus for the ASX listing and the IPO capital raise working closely with the lead manager.
Argenica listed on the ASX in June 2021 at 20c, and traded as high as $1.02 during 2022.